Preserving fertility in female cancer patients through ovarian tissue freezing
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients
This study is testing a method to freeze ovarian tissue for female cancer patients who don't have time for regular fertility preservation, helping them protect their ability to have children later.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 1 Month to 35 Years |
| Sex | Female |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05830929 on ClinicalTrials.gov |
What this trial studies
This project aims to provide ovarian tissue cryopreservation for female cancer patients who lack sufficient time for traditional fertility preservation methods like oocyte or embryo freezing. The approach includes consultations with fertility specialists to discuss the procedure and associated risks. Following the collection of ovarian tissue via surgery, the tissue will be cryopreserved using either slow freezing or vitrification techniques. This method is particularly beneficial for prepubertal girls and those undergoing treatments that may harm their fertility.
Who should consider this trial
Good fit: Ideal candidates are female cancer patients aged 0-35 who are at risk of fertility loss due to their treatment.
Not a fit: Patients who are pregnant or those without anticipated oncologic therapies may not benefit from this procedure.
Why it matters
Potential benefit: If successful, this could enable female cancer patients to preserve their fertility and have the option to conceive in the future.
How similar studies have performed: Other studies have shown promise in fertility preservation techniques, making this approach a valuable option for patients facing similar challenges.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients * Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments; * Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future. Exclusion Criteria: * Patients with no anticipated oncologic therapies * Patients who are pregnant * Children with one ovary * Children deemed high risk for perioperative complications * Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
Where this trial is running
Hong Kong
- Prince of Wales Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Jacqueline Pui Wah CHUNG, MBBS — Chinese University of Hong Kong
- Study coordinator: Elaine NG, MPhil
- Email: elaineng@cuhk.edu.hk
- Phone: +852 35052745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.